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Abstract
Six different adjuvants, each in combination with inactivated polio vaccine (IPV) produced with
attenuated Sabin strains (sIPV), were evaluated for their ability to enhance virus neutralizing
antibody titers (VNTs) in the rat potency model. The increase of VNTs was on average 3-, 15-,
24-fold with adjuvants after one immunization (serotype 1, 2, and 3, respectively). Also after a
boost immunization the VNTs of adjuvanted sIPV were on average another 7- 20- 27 times higher
than after two inoculations of sIPV without adjuvant. The results indicate that it is feasible to
increase the potency of inactivated polio vaccines by using adjuvants.
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1. Introduction
After wild polioviruses are eradicated, the live-attenuated oral poliovirus vaccine (OPV)
viruses will be the only source of live poliovirus in the world. These attenuated strains can
revert to neurovirulence and cause paralysis. In addition, this neurovirulent virus may then
spread among a population as circulating vaccine-derived polioviruses (cVDPV) [1]. To
minimize the risks of cVDPV, OPV use should eventually stop. Instead, safe and affordable
IPV or, from a biosafety in manufacturing viewpoint, preferably sIPV, will be necessary for
countries that wish to continue polio immunization. The National Institute of Public Health
and the Environment (RIVM) has developed a candidate sIPV vaccine [2, 3] The production
costs of sIPV are currently estimated equivalent to that for IPV, which is about 20-fold more
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expensive than OPV [4]. To replace OPV, costs should decrease further, for instance by
antigen reduction using adjuvants.
Preclinical studies have already demonstrated the enhancing effect of some adjuvants in
combination with IPV. Both oil-in-water emulsion and aluminium hydroxide enhance
potency in rats [4]. Ivanow et al described the enhanced mucosal and systemic immune
responses by 1,25-Dihydroxyvitamin D3 [5]. Also, CpG oligodeoxynucleotides as well as
aluminium hydroxide can significantly enhance both the humoral and cellular immune
responses to sIPV in mice [6]. In the current study, we optimised sIPV potency through
formulation with six adjuvants: aluminium hydroxide, two squalene-in-water emulsions, two
lipopolysaccharide (LPS) derivatives, and Venezuelan equine encephalitis (VEE) replicon
particles (GVI3000).
Aluminium salts are the most frequently used vaccine adjuvants. They may serve as an
antigen depot, resulting in slow release of the antigen if it is adsorbed. Therefore, high
adsorption levels are usually favourable and the degree of adsorption should be determined
[7].
Emulsions are widely known as potent adjuvant systems [8–10]. Oil-in-water emulsions
contain metabolisable oil like squalene, e.g. MF59® (Novartis Vaccines and Diagnostics),
which has been used extensively in influenza vaccines.
Two LPS-derivatives were also included in this study. LPS is a TLR4 ligand and stimulates
a variety of cells to produce cytokines and chemokines that control dendritic cell trafficking
and maturation. Because of its toxicity, LPS cannot be used as an adjuvant. However,
chemically detoxified LPS, monophosphoryl lipid A (MPLA), is at least 100 times less toxic
than LPS but retains strong adjuvant activity [11]. MPLA in combination with aluminium
salts is present in the HPV vaccine Cervarix® and HBV vaccine Fendrix®
(GlaxoSmithKline Biologicals). Genetically modified PagL LPS is obtained through the
expression of the Bordetella bronchiseptica PagL gene in Neisseria meningitidis. PagL
expression leads to Lipid A deacylation at the 3 position and a reduced toxicity compared to
wild type LPS [12].
GVI3000 lacks genes for VEE structural proteins, which are provided in trans during
production, but retains the information for replication [13]. GVI3000 is infectious,
undergoes only a single round of replication and cannot further propagate. The viral RNA
and/or partially dsRNA replication intermediates, may act as an adjuvant by stimulating the
innate immune response in dendritic cells [14, 15] . In mouse models, GVI3000 enhances
humoral and cellular responses in both systemic and mucosal compartments [8, 14].
To achieve dose sparing we tested the different adjuvant formulations with sIPV in the
standard rat IPV potency test, which consists of one immunization, measuring VNTs in
serum [16]. We also added a second immunization to determine the effect of boosting.
2. Materials and methods
2.1 Vaccine preparation
sIPV was produced under cGMP according to a slightly modified wild type (wt) IPV
production process [2]. Sabin poliovirus (type 1: LSc 2ab KP2; type 2: P712 Ch2ab-KP2;
type 3: Pfizer 457-III) virus was produced on Vero cells, grown on microcarriers in a
bioreactor. Virus was purified by filtration, gel permeation chromatography and DEAE ion
exchange chromatography (GE Healthcare). Formaldehyde inactivation was performed
according to WHO requirements [17]. The vaccine was administered in 0.4–0.6–1.2 DU/rat
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for type 1, 2, and 3 respectively (unless stated differently) which corresponds with 10 ng for
type 1, 50 ng for type 2, and 50 ng virus protein for type 3 [3].
2.2 Adjuvant formulations
Aluminium salts The adsorption behaviour of monovalent sIPV to aluminium phosphate
(Adjuphos 2%, Brenntag, Denmark) and aluminium hydroxide (Alhydrogel 2%, Brenntag,
Denmark) was determined as a function of temperature (4°C and 22°C), incubation time
(0.5–16 h), NaCl concentration (25-144-500 mM) and phosphate concentration (1-10-100
mM). Prior to adsorption the D-antigen concentrations of the individual monovalent Sabin
IPV batches were diluted to 10-16-32 DU/ human dose for type 1, 2, and 3, respectively, and
adjusted to pH 7. Adsorption was determined by measuring the D-antigen in supernatant of
pelleted vaccine. D-antigen concentrations were measured with biosensor analysis [3]. For
immunization studies, aluminium salt was diluted with vaccine medium to 0.5 mg
aluminium salt per dose.
Oil in water (o/w) emulsion #1 (EM030) was manufactured at IDRI, Seattle, USA [18] to
contain 10% (v/v) squalene, 1.8% (v/v) glycerol, 1.9% (w/v) egg phosphatidylcholine and
0.09% (w/v) Pluronic® F68 in 25mM ammonium phosphate buffer, pH ~5.5. Particle size
(dynamic light scattering (DLS), was ~95 nm (polydispersity index (PI) 0.04). The emulsion
was diluted with vaccine medium to 2% (v/v) squalene and mixed gently for 30 seconds
prior to immunization. The pH of the final vaccine was ~6.9.
O/w emulsion #2 (SWE02) was manufactured by the Vaccine Formulation Laboratory [19,
20] at the University of Lausanne (Epalinges, Switzerland) and contained 3.9% (w/v)
squalene, 0.5% (w/v) Tween® 80 and 0.5% (w/v) Span® 85 in 10mM citrate buffer. The
particle size was as determined by DLS 140±3 nm (PI 0.07). The emulsion was diluted 1:1
with antigen and mixed gently for 30 seconds prior to immunization. The pH of the final
vaccine was ~6.5.
PagL LPS was generated at RIVM as decribed previously [12]. PagL LPS concentration in
the vaccine was 1 μg/vaccine dose.
Monophosphoryl Lipid A (MPLA) (InvivoGen, San Diego, USA) was added to the vaccine
at a final concentration of 1 μg/vaccine dose prior to immunization.
GVI3000 replicon particles were manufactured at Global Vaccines Inc. (Research Triangle
Park, NC 27709, United States) [13, 21, 22]. GVI3000 was produced by electroporation of
BHK-21 cells with the replicon genome along with two helper RNAs. The replicon particles
used in this study were packaged in the wild-type (V3000) envelope [23]. After purification,
the absence of detectable propagation-competent virus was confirmed by cytopathic effect
assay. GVI3000 was titered by immunofluorescence of VEE non-structural proteins in
infected BHK-21 cells. Prior to immunization GVI3000 was mixed with antigen-medium
solution in a final concentration of 105 infectious units (IU)/vaccine. GVI3000 was
previously referred to as VRP (Tonkin in Vaccine 2010 and 2012).
2.3 Immunizations
Outbred Rivm:TOX rats, 175–250g, were used. The experiments were performed using
males and females (1:1) which are evenly distributed between all groups. Groups of 14–16
rats were immunized twice 4 weeks apart, intramuscularly (i.m.) with 100μl in the hind
limb.
The animals were bled 21 days after the first immunization by orbital puncture and 21 days
after the boost immunization by heart puncture. Sera were stored at −20°C.
Westdijk et al. Page 3
Vaccine. Author manuscript; available in PMC 2014 February 18.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2.4 Virus neutralization assay
Neutralizing antibodies against all three poliovirus types were measured separately
inoculating Vero cells with 100 CCID50 of the wild-type strains (Mahoney, MEF-1 and
Saukett). The sera were inactivated at 56°C for 30 minutes prior to testing. Two-fold serial
dilutions were made from 21 (1:2) to 224 (1:16777216). Serum/virus (100 CCID50/50 μl)
mixtures were incubated 3 hours at 36°C and 5% CO2 and subsequently overnight at 5°C. 50
μl 2×105 Vero cells/ml was added. After 7 days of incubation (36°C and 5% CO2) the plates
were stained and fixed with crystal violet and the results were read macroscopically. Virus
neutralizing titers were expressed as the last serum dilution that has an intact monolayer (no
signs of cytopathogenic effect)[24].
2.5 Serological testing
Serology was performed for sIPV type 2 only. The poliovirus-specific IgG subclasses were
determined with a sandwich ELISA. Biosensor analysis was used to determine the
dissociation rate of poliovirus-specific rat sera. More detailed descriptions of the serological
assays are provided as supplementary material and methods.
2.6 Statistical analysis
The Mann-Whitney two-tailed test was used for statistical analysis (GraphPad Prism 5.00
for Windows (GraphPad Software, San Diego, USA). p values < 0.05 were considered
significant.
3. Results
3.1. Aluminium phosphate or aluminium hydroxide
Adsorption to aluminium hydroxide was 100% for all serotypes at low phosphate
concentration, whereas temperature, time and NaCl-concentration had no effect in the range
of parameters tested here. Adsorption to aluminium phosphate was serotype-dependent, pH-
dependent and often incomplete (results not shown). Importantly, the potency of sIPV was
affected by the degree of adsorption (Table I). At pH 7 the relative potency of sIPV as
measured in the regular rat potency test [16], formulated with either aluminium phosphate or
aluminium hydroxide was approximately 3-fold increased for type 1 and type 2. Also the
potency of type 3, formulated with aluminium hydroxide increased by a factor of two.
However, aluminium phosphate had no effect on type 3 potency. This is in line with the
degree of adsorption of polio type 1, 2 and 3: all three types adsorbed 100% to aluminium
hydroxide. Type 3 did not adsorb to aluminium phosphate at all and type 2 adsorbed 43±9%
(n=3) to aluminium phosphate. Based on these results further work was done with
aluminium hydroxide.
For a good comparison of the enhancing effect of the different adjuvants we have chosen a
vaccine dose that is low without adjuvant in the linear region of the dose response curve
(0.4, 0.6, and 1.2 DU for sIPV type 1, 2 and 3, respectively) except for the aluminum
hydroxide experiments. Because these batches were part of a clinical trial, the potency of
these batches was tested in the regular rat potency test with several doses of D-antigen (fig.
1). A dose response could be seen with sIPV although the VNTs were not significantly
different between the highest doses of type 1 (10 DU and 3.3 DU), type 2 (16 DU and 5.3
DU) and type 3 (32 DU and 10.7 DU) (fig. 1). The adjuvanted sIPV induced a significantly
higher VNT than plain sIPV for type 2 at all doses and for serotype 3 at a dose of 3.6 DU.
Aluminium hydroxide had no significant effect on sIPV type 1 although the adjuvanted type
1 VNTs tended to be higher than the VNTs of plain sIPV type 1.
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3.2 Oil in water (o/w) emulsion #1 (EM030)
Rats (15 per group) were immunized twice at an interval of 28 days with 0.4, 0.6, and 1.2
DU for sIPV type 1, 2 and 3, respectively. Sera obtained at day 21 showed that emulsion #1
addition to sIPV significantly enhanced the VNT response for antibodies against serotype 2
and 3 but not antibodies against serotype 1 (Fig. 2A). A clear booster effect was seen at day
49 for both plain and adjuvanted sIPV. Although VNT levels at day 49 were already
enhanced for plain sIPV (group means of about 29 or higher, Fig. 2B), for adjuvanted sIPV
type 2 and 3 the increase of VNTs was still significant.
3.3 O/w emulsion #2 (SWE02), PagL LPS, MPLA
sIPV was mixed with PagL LPS or MPLA or SWE02 or with combinations of these
adjuvants. Figure 3 shows a significant increase in VNT on day 21 against all three
serotypes when rats were immunized with sIPV and SWE02 or PagL LPS. The increase in
VNT was not significantly different between these two types of adjuvant. The combination
o/w emulsion and PagL LPS or MPLA did not enhance the virus neutralizing antibody titers
further.
Post-boost VNTs on day 49 were clearly increased for all adjuvants with sIPV and sIPV
alone compared to day 21 (Fig.3B, 3D and 3F). After boost, VNTs of all adjuvanted sIPV
groups were significantly higher than plain sIPV for type 3, PagL LPS for type 2, but none
for type 1. Differences between the kind of adjuvant or between single adjuvant and
combinations of adjuvants were not significant (one-way analysis of variance, α=0.05).
3.4 GVI 3000
sIPV was also mixed with 105 I.U. GVI3000 adjuvant in a prime and boost rat potency
experiment identical in design to Figures 2, 3, and 4. GVI3000 was the only adjuvant that
significantly enhanced the VNTs to all three poliovirus serotypes at both day 21 and day 49
compared to vaccine alone (Fig. 4). At day 21 VNTs increased 2-8-32 fold for type 1, 2 and
3 respectively. The increase in VNT was even higher at day 49, from 16-fold (type 1 and 3)
to 32-fold (type 2). In addition, a clear booster effect was seen for both plain and adjuvanted
sIPV at day 49 compared to day 21.
3.5 Serology
Rat sera of the experiment in which sIPV type 2 was mixed with PagL LPS or MPLA and/or
SWE02 were serologically tested. IgG2b titers were significantly enhanced after
administration of o/w emulsion in rat sera at both day 21 and day 49 (Supplemental Fig.
S1A, B). PagL LPS induced significantly more IgG1 and IgG2a after prime and boost
immunization (Fig. S1E–H). PagL LPS and MPLA and mixtures of these adjuvants with
SWE02 boosted the IgG2c response after prime immunisation. After boost immunisation
IgG2c titers were also significantly enhanced by PagL but significantly decreased by
SWE02+MPL (Supplemental Fig.S1C, D).
The real-time binding of serum antibodies to antigen allows monitoring the association and
dissociation of antibodies. Antibody avidity was estimated by measuring percentage loss of
antibodies bound to immobilized type 2 wt polio vaccine using a biosensor analysis.
Surprisingly, at day 49 a higher loss of antibody binding was found as compared to day 21
which was significant (P<0.05) for the SWE02 group and the SWE02+PagL LPS group
(p<0.0001), indicating that antibodies induced by a boost immunization tend to have a lower
avidity than antibodies after prime immunization (Supplemental Fig. S2). However, the
poliovirus specific-antibodies induced by adjuvanted IPV tend to be more avid than
antibodies induced by sIPV alone.
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4. Discussion
Six adjuvants have been compared in this study. Table 2 shows a summary of the adjuvant
effect of the investigated adjuvants. The increase in VNT of the aluminum hydroxide
adjuvanted sIPV (1-, 8-, and 4-fold for type 1, 2, and 3 sIPV respectively), is more or less in
agreement with previous findings [4, 6]. The adjuvant effect of MPLA was similar to that of
aluminium hydroxide. In the experiments with o/w emulsions (EM030 and SWE02), we saw
significantly higher responses compared to plain sIPV to all three serotypes after a prime
immunization at low doses of adjuvanted sIPV. By further serum dilution, we saw that
EM030 induced a 60-fold increase in anti-type 2 antibody titers after prime immunization
compared to 2- to 11-fold increase with other adjuvants. SWE02 however, induced a mere
6-fold increase of anti-type 2 antibody titer (Table 2). Baldwin et al [4] used the same o/w
emulsions in their study with wt IPV. In that study, stable emulsion (SE), which is the same
as EM030, also induced greater antibody titers against type 2 than EM1, which is the same
as SWE02. O/w emulsions like EM030 and SWE02 have all different components and their
adjuvanticity usually varies a lot with the type of antigen, buffer, pH, route of
administration, animal model etc.[18, 25–27]. The adjuvant effect at day 21 of SWE02,
PagL LPS, and GVI3000 are close together with fold increases of 2–5, 5–11 and 24–42 for
Sabin type 1, 2 and 3, respectively.
Although PagL LPS caused significant increases in VNTs which was comparable to the
immunogenicity responses caused by o/w emulsions, combinations of PagL LPS or MPLA
in o/w emulsion did not induce higher antibody responses than the single adjuvants.
Interestingly, Garçon et al [28] showed that the formulation of malaria-antigen with o/w
emulsion in combination with 3D-MPL was also not significantly different from the
formulation of malaria vaccine with o/w emulsion alone. Only, when QS21 was added to the
formulation the adjuvant system (AS02: o/w, 3D-MPL and QS21) was capable of eliciting
high antibody titers.
OPV, better than IPV/sIPV, can induce mucosal immunity to poliovirus infection in the gut,
which also helps prevent transmission [29]. The GVI3000 adjuvant uniquely induces
mucosal immunity in mice even when delivered intramuscularly with IPV [Jorquera,
manuscript in preparation];[13]. Thus, a GVI3000-sIPV vaccine may be ideal to replace
OPV without losing the ability to induce mucosal immunity and additionally allowing for
antigen sparing of sIPV.
Contrary to the finding of Baldwin et al [4] a second administration of plain sIPV boosted
the VNT response enormously. In addition, a clear enhancing effect of the adjuvants of
experiment 2–4 was seen after boost (Table 2).The variation in VNT response after a boost
of sIPV alone between three experiments was substantial. This may be attributed to a large
animal-to-animal variability (the use of outbred rats).
Aluminium salts and oil-in-water emulsions are usually considered as Th2-adjuvants ([8, 30]
whereas MPLA and PagL LPS are usually more Th1-inducing adjuvants [8, 31]. In the rat
IgG1 antibodies can be assigned to a Th2- and IgG2b and IgG2c to a Th1-dependent
immune response, where IgG2a is also indicative of a Th1 pathway [32, 33]. Remarkably, in
our study it is just the opposite: oil-in water emulsion SWE02 boosted a polio-specific
IgG2b response (Supplemental Fig. S1A–B) where PagL LPS boosted a clear IgG1 and
IgG2a response (Supplemental Fig. S1 E–H). As little is known about poliovirus specific T
cell responses in rats, further research will be necessary to determine the relative roles of
antibodies and the influence of adjuvants on cellular immunity in rats.
PagL LPS and GVI3000 are both adjuvants that have not yet been clinically tested but both
may contribute to a wider choice of adjuvants in the future.
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Summarizing, the results of this study indicate that it is feasible to increase the potency of
sIPV by using adjuvants. Nevertheless, although we demonstrated that most of the adjuvants
are dose sparing, since cost-reduction is a main issue in replacing OPV with sIPV a
thorough investigation into production costs of each adjuvant is recommended.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors are grateful to Lonneke Levels for statistical support and Debbie Brugmans for technical assistance.
This work was supported by the World Health Organization using funds provided by a grant from the Bill and
Melinda Gates Foundation, by a U.S. National Institute of Health grant U01-AI070976 to GVI, and by the Bill and
Melinda Gates Foundation grant #42387 to IDRI.
References
[1]. Sutter RW, Caceres VM, Mas Lago P. The role of routine polio immunization in the post-
certification era. Bull World Health Organ. Jan; 2004 82(1):31–9. [PubMed: 15106298]
[2]. Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, et al.
Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus
strains to shift from Salk-IPV to Sabin-IPV. Vaccine. Sep 22; 2011 29(41):7188–96. [PubMed:
21651934]
[3]. Westdijk J, Brugmans D, Martin J, van't Oever A, Bakker WA, Levels L, et al. Characterization
and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for
inactivated polio vaccines. Vaccine. Apr 18; 2011 29(18):3390–7. [PubMed: 21397718]
[4]. Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an
inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine. Jan 17; 2011 29(4):644–
9. [PubMed: 21134451]
[5]. Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-dihydroxyvitamin d3 enhances systemic and
mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis. Feb 15; 2006
193(4):598–600. [PubMed: 16425140]
[6]. Yang C, Shi H, Zhou J, Liang Y, Xu H. CpG oligodeoxynucleotides are a potent adjuvant for an
inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine. Aug 31.2009
[7]. (EMEA) EMA; Committee for medicinal products for human use (CHMP). Guideline on
adjuvants in vaccines for human use. 2004 EMEA/CHMP/VEG/134716/2004.
[8]. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B.
Vaccine adjuvants: current challenges and future approaches. J Pharm Sci. Apr; 2009 98(4):
1278–316. [PubMed: 18704954]
[9]. Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S, Auray G, Eng N, Garlapati S, et al.
Combination adjuvants: the next generation of adjuvants? Expert Rev Vaccines. Jan; 2011 10(1):
95–107. [PubMed: 21162624]
[10]. Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules. 2009; 14(9):
3286–312. [PubMed: 19783926]
[11]. Ribi E, Amano K, Cantrell J. Preparation and antitumor activity of nontoxic lipid A. Cancer
Immunol Immunother. 1982; 12(2):91–6.
[12]. Arenas J, van Dijken H, Kuipers B, Hamstra HJ, Tommassen J, van der Ley P. Coincorporation
of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis
opacity protein: influence on endotoxic and adjuvant activity. Clin Vaccine Immunol. Apr; 2010
17(4):487–95. [PubMed: 20107001]
[13]. Tonkin DR, Jorquera P, Todd T, Beard CW, Johnston RE, Barro M. Alphavirus replicon-based
enhancement of mucosal and systemic immunity is linked to the innate response generated by
primary immunization. Vaccine. Apr 19; 2010 28(18):3238–46. [PubMed: 20184975]
Westdijk et al. Page 7
Vaccine. Author manuscript; available in PMC 2014 February 18.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
[14]. Thompson JM, Whitmore AC, Konopka JL, Collier ML, Richmond EM, Davis NL, et al.
Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S
A. Mar 7; 2006 103(10):3722–7. [PubMed: 16505353]
[15]. Tonkin DR, Whitmore A, Johnston RE, Barro M. Infected dendritic cells are sufficient to mediate
the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.
Vaccine. Jun 22; 2012 30(30):4532–42. [PubMed: 22531556]
[16]. van Steenis G, van Wezel AL, Sekhuis VM. Potency testing of killed polio vaccine in rats. Dev
Biol Stand. 1981; 47:119–28. [PubMed: 6262142]
[17]. WHO. World Health Organisation. Requirements for poliomyelitis vaccine (inactivated) World
Health Organ Tech Rep Series. 2002; 910:32e65. Annex 2.
[18]. Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick TS. Monitoring the effects of
component structure and source on formulation stability and adjuvant activity of oil-in-water
emulsions. Colloids Surf B Biointerfaces. Aug 1; 2008 65(1):98–105. [PubMed: 18440205]
[19]. Collin N, Dubois PM. The Vaccine Formulation Laboratory: a platform for access to adjuvants.
Vaccine. Jul 1; 2011 29(Suppl 1):A37–9. [PubMed: 21684427]
[20]. Ventura R, Brunner L, Heriyanto B, de Boer O, O'Hara M, Huynh C, et al. Technology transfer
of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in
Indonesia. Vaccine. Aug 7.2012
[21]. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems
from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro
and immunization against heterologous pathogens in vivo. Virology. Dec 22; 1997 239(2):389–
401. [PubMed: 9434729]
[22]. Davis NL, Caley IJ, Brown KW, Betts MR, Irlbeck DM, McGrath KM, et al. Vaccination of
macaques against pathogenic simian immunodeficiency virus with Venezuelan equine
encephalitis virus replicon particles. J Virol. Jan; 2000 74(1):371–8. [PubMed: 10590126]
[23]. Davis NL, Powell N, Greenwald GF, Willis LV, Johnson BJ, Smith JF, et al. Attenuating
mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of
single and multiple mutants in a full-length cDNA clone. Virology. Jul; 1991 183(1):20–31.
[PubMed: 2053280]
[24]. Albrecht P, van Steenis G, van Wezel AL, Salk J. Standardization of poliovirus neutralizing
antibody tests. Rev Infect Dis. May-Jun;1984 6(Suppl 2):S540–4. [PubMed: 6330853]
[25]. Fox CB, Lin S, Sivananthan SJ, Dutill TS, Forseth KT, Reed SG, et al. Effects of emulsifier
concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water
emulsions. Pharm Dev Technol. Oct; 2011 16(5):511–9. [PubMed: 20550484]
[26]. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. Immunomodulatory and physical
effects of oil composition in vaccine adjuvant emulsions. Vaccine. Nov 28; 2011 29(51):9563–
72. [PubMed: 21906648]
[27]. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. Immunomodulatory and Physical
Effects of Phospholipid Composition in Vaccine Adjuvant Emulsions. AAPS PharmSciTech.
Mar 14.2012
[28]. Garcon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria
vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines. Apr; 2003 2(2):231–
8. [PubMed: 12899574]
[29]. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal
immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis. Jan;
1991 163(1):1–6. [PubMed: 1845806]
[30]. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved
adjuvants. Curr Opin Immunol. Feb; 2009 21(1):23–9. [PubMed: 19246182]
[31]. Steeghs L, Keestra AM, van Mourik A, Uronen-Hansson H, van der Ley P, Callard R, et al.
Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1
of Neisseria meningitidis. Infect Immun. Aug; 2008 76(8):3801–7. [PubMed: 18490457]
[32]. Gracie JA, Bradley JA. Interleukin-12 induces interferon-γ-dependent switching of IgG
alloantibody subclass. Eur J Immunol. 1996; 26(6):1217–21. [PubMed: 8647195]
Westdijk et al. Page 8
Vaccine. Author manuscript; available in PMC 2014 February 18.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
[33]. Jakel T, Khoprasert Y, Kliemt D, Mackenstedt U. Immunoglobulin subclass responses of wild
brown rats to Sarcocystis singaporensis. Int J Parasitol. Mar; 2001 31(3):273–83. [PubMed:
11226454]
Westdijk et al. Page 9
Vaccine. Author manuscript; available in PMC 2014 February 18.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Highlights
• Six adjuvants with Sabin inactivated poliovirus vaccine were evaluated in rats
• The increase of neutralizing antibodies was 3-,15-, 24-fold for type 1, 2 and 3
• After boost the increase was another 7-, 20-, 27-fold
• It is feasible to increase the potency of polio vaccine by adjuvants
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Fig. 1.
(wt polio)Virus neutralizing antibody titers from rats (n=10/group) 21 days after one
immunization with various doses of inactivated Sabin polio vaccine (with or without
aluminium hydroxide) type 1 (A), type 2 (B), and type 3 (C), respectively. Each symbol
represents the titer of one individual rat and means are indicated by horizontal bars. Sera that
were positive at the highest dilution (1:4096), i.e. titer is equal or larger than 13 are
represented as 13(log2); sera that were negative at the 1:2 dilution are designated as 1.
Statistical significance to sIPV was determined by the Mann-Whitney two-tailed test using
GraphPad Prism version 5. *P <0.05, **P <0.01.
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Fig. 2.
(wt polio)Virus neutralization antibody titers from rats (n=15/group) 21 days following a
prime (A) and boost (B) immunization (day 28) with 0.4–0.6–1.2 DU/rat for sIPV type 1, 2
and 3 (with or without EM030), respectively. Each symbol represents the titer of one
individual rat and means are indicated by horizontal bars. Sera that were negative at the 1:2
dilution are designated as 1. Statistical significance to sIPV was determined by the Mann-
Whitney two-tailed test using GraphPad Prism version 5. *P <0.05, **P <0.01, ***P<0.001.
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Fig. 3.
(wt polio)Virus neutralization antibody titers against poliovirus type 1 (A, B), type 2(C, D)
or type 3 (E, F) from rats (n=14/group) 21 days following a prime (A, C, E) and boost (B, D,
F) immunization (day 28) with 0.4–0.6–1.2 DU/rat sIPV type 1, 2 and 3 respectively (with
or without adjuvant). Each symbol represents the titer of one individual rat and means are
indicated by horizontal bars. Sera that were negative at the 1:2 dilution are designated as 1.
Statistical significance to sIPV was determined by the Mann-Whitney two-tailed test using
GraphPad Prism version 5. *P <0.05, **P <0.01, ***P<0.001, ****P<0.0001.
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Fig. 4.
(wt polio)Virus neutralization antibody titers against poliovirus type 1, type 2 or type 3 from
rats (n=14/group) 21 days following a prime (A) and boost (B) immunization (day 28) with
0.4-0.6-1.2 DU/rat sIPV type 1, 2 and 3 respectively (with or without GVI3000). Each
symbol represents an individual titer and the line indicates the group mean. Statistical
significance relative to plain sIPV was determined by the Mann-Whitney two-tailed test
using GraphPad Prism version 5. *P <0.05, **P <0.01, ***P<0.001.
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Table I
Relative potency of plain or adsorbed sIPVa against WHO reference Pu91-01 (40-8-32 DU/dose) with a
potency of 1 for types 1, 2, and 3, respectively
DU/dose Relative potency (95% confidence interval)b
Type Nominal Plain + Aluminium Phosphate Adsorption to
Aluminium
Phosphate (%)
+ Aluminium Hydroxide Adsorption to
Aluminium
Hydroxide (%)
Type 1 20 1.63 5.16 100 4.92 100
(0.65 – 3.62) (3.02 – 10.41) (2.48 – 9.11)
Type 2 40 0.12 0.38 43 ± 9c 0.40 100
(0.06 – 0.20) (0.26 – 0.59) (0.25 – 0.64)
Type 3 32 0.97 0.80 0 1.60 100
(0.57 – 1.67) (0.51 – 1.23) (1.19 – 2.17)
a
Experimental vaccine
b
The relative potency was calculated with the parallel line method. A relative potency of 1 means equal potency (per DU) as compared to the
reference preparation
c(n=3)
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Table II
Increase in VNTa adjuvanted sIPV compared with plain sIPV
day 21 x--fold day 49 x--fold
Rat Experiment Adjuvant/plain Type 1 Type 2 Type 3 Type 1 Type 2 Type 3
1 Al(OH)3b 1 8*c 4 - - -
2 Plain sIPV 1 1 1 128d 60 630
EM030 2 60* 32* 384 420* 3780*
3 Plain sIPV 1 1 1 42 17 56
SWE02 5* 6* 42* 126 102 2912*
PagL LPS 2* 5* 24* 294 578* 2352*
MPLA 2 2 9* 210 68 952*
4 Plain sIPV 1 1 1 26 37 194
GVI3000 3* 11* 32* 390* 1813* 3104*
a
The increase in VNTs of the adjuvanted groups is based on the difference between the mean 2log score of the adjuvanted group at day 21 and 49,
respectively, and the mean 2log score of the plain sIPV group at day 21
b
For the aluminium hydroxide experiment we used the data obtained with 0.4 −0.6 −1.2 DU for serotype 1, 2, and 3, respectively
c
The asterisks depict the significant differences of the adjuvanted groups compared to plain sIPV at day 21 and day 49, respectively
d
The increase in VNT of plain sIPV at day 49 is based on the difference between the mean 2log score of the plain sIPV group at day 49 and the
mean 2log score of the plain sIPV group at day 21
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